Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Blood. 2021 Jun 3;137(22):3145-3148. doi: 10.1182/blood.2020009759.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Humans
  • Immunotherapy, Adoptive*
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Proof of Concept Study
  • Receptors, Chimeric Antigen / administration & dosage*

Substances

  • Receptors, Chimeric Antigen